Original Sky Meter Intranet
Highlights
On May 16, the official website of the State Food and Drug Administration announced that the application for traditional Chinese medicine protection of Qiwei Tongbi Oral Liquid was accepted. The product is Kangyuan Pharmaceutical's exclusive rheumatic disease treatment drug (including exclusive dosage form, the same below), and the sales growth rate of China's public medical institution terminal and online pharmacy terminal in 2023 will exceed 12% and 35%, respectively.
Source: official website of the State Food and Drug Administration
Qiwei Tongbi Oral Liquid is the exclusive Chinese patent medicine of Kangyuan Pharmaceutical, which has the effect of tonifying the kidney and strengthening the bones, dispelling wind and paralysis, and is mainly used to treat rheumatoid arthritis syndrome with liver and kidney insufficiency and rheumatism obstruction syndrome.
Sales Trend of Terminal Qiwei Tongbi Oral Liquid in China's Public Medical Institutions in Recent Years (Unit: 10,000 Yuan)
Source: Minenet's competitive landscape of drug terminals in China's public medical institutions
Since entering the National Medical Insurance Catalogue in 2017, Qiwei Tongbi Oral Liquid has achieved rapid growth in terminal sales in China's urban public hospitals, county-level public hospitals, urban community centers and township health centers (hereinafter referred to as China's public medical institutions), reaching a peak of about 47 million yuan in 2019, and sales declined under the influence of the epidemic in 2020, and resumed positive growth from 2021, with nearly 40 million yuan in sales revenue in 2023, and ascended to the TOP1 throne of rheumatic disease drug solution; In the online pharmacy terminal, the sales growth rate of the drug will be as high as 35.19% in 2023, and the market potential is promising.
Kangyuan Pharmaceutical Co., Ltd. was previously in the protection period of the second-class protected varieties of traditional Chinese medicine
Source: Minenet Catalogue Database of Protected Varieties of Traditional Chinese Medicine
According to data from Minenet, before this, Kangyuan Pharmaceutical had 2 second-level protected varieties of traditional Chinese medicine in the protection period, namely Jiuwei Qufeng Granules for the treatment of pediatric multiple tics (protection termination date: October 29, 2025), and Epimedium total flavonoid capsules for the treatment of osteoporosis (protection termination date: September 5, 2029), covering pediatric convulsion drugs, osteoporosis drugs and other treatment subclasses.
Source: Minenet database, official website of the State Food and Drug Administration
Note: The statistical scope of "Drug Terminal Competition Pattern of China's Public Medical Institutions" by Minenet is: China's urban public hospitals, county-level public hospitals, urban community centers and township health centers, excluding private hospitals, private clinics and village clinics; The statistical scope of "China's Online Pharmacy Terminal Competition Pattern" is: all drug data of online pharmacies across the country, including all online pharmacy drug data on third-party platforms such as Tmall and JD.com, as well as private domain platforms; The above sales are calculated based on the average retail price of the product at the terminal. The statistics are as of May 17, if there is any omission, please correct!